Jacobs Levy Equity Management
KRON

Jacobs Levy Equity Management’s Kronos Bio KRON Stock Holding History

Jacobs Levy Equity Management’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-300,968
Closed -$286K – 1146
2024
Q4 		$286K Sell
300,968
-105,796
-26% -$99.8K ﹤0.01% 874
2024
Q3 		$407K Sell
406,764
-33,973
-8% -$37.6K ﹤0.01% 858
2024
Q2 		$547K Buy
440,737
+381,339
+642% +$388K ﹤0.01% 825
2024
Q1 		$77.2K Sell
59,398
-234,132
-80% -$267K ﹤0.01% 917
2023
Q4 		$367K Buy
293,530
+242,716
+478% +$269K ﹤0.01% 867
2023
Q3 		$66.1K Sell
50,814
-4,451
-8% -$7.19K ﹤0.01% 948
2023
Q2 		$95.1K Buy
+55,265
New +$87.7K ﹤0.01% 947

Other funds holding KRON

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Jacobs Levy Equity Management's KRON Position: Q1 2025 in Review

Jacobs Levy Equity Management sold out of Kronos Bio (KRON) in Q1 2025, closing a stake of 300,968 shares — an estimated $286K sold.

Jacobs Levy Equity Management first reported a position in KRON in Q2 2023 and held it in 7 quarters. The position peaked at $547K in Q2 2024. 47 funds tracked by Wall St. Rank hold KRON as of Q1 2025.

  • Jacobs Levy Equity Management reported no remaining Kronos Bio position as of Q1 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 300,968 Kronos Bio shares in Q1 2025, an estimated $286K.
  • Jacobs Levy Equity Management first reported a position in Kronos Bio in Q2 2023 and held it in 7 quarters.
  • Jacobs Levy Equity Management's Kronos Bio position peaked at $547K in Q2 2024.
  • 47 funds tracked by Wall St. Rank held Kronos Bio as of Q1 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2025, filed 15 May 2025.